Real world study finds Pfizer-BioNTech Covid-19 vaccine to be 92% effective
16 April
Shane Oliver, an economist, retweeted an article on a real-world study of more than one million people in Israel, and the effect of the Pfizer-BioNTech Covid-19 vaccine (BNT162b2 mRNA) in a nationwide mass vaccination settling.
The study revealed vaccine effectiveness against the coronavirus infection to be 92%, seven days after being administered the second dose.
Estimated effectiveness in preventing death from Covid-19 was 72% for 14 days through 20 after the first dose.
Effectiveness in specific subgroups of the population assessed for documented infection and symptomatic Covid-19 was consistent across age groups, with slightly lower effectiveness in people with other multiple co-existing conditions.
The study confirmed that the vaccine is effective for a wide range of Covid-19-related outcomes, a finding that is consistent with the results of the randomised trial.
